Research
Blocking receptor signals can help treat fibrosis
The Brief
- An investigator-initiated trial showed that inhibiting the cytokines IL-4 and IL-13 can prevent fibrosis in localized scleroderma, a skin disease.
- The researchers suggest the findings could pave the way for preventing and treating other fibrotic conditions.
- The source summary is brief and does not give trial size, dosing, or detailed results.
Why it matters
The result points to IL-4 and IL-13 signalling as a possible target for stopping fibrosis, a process relevant to many diseases beyond localized scleroderma.
Who’s affected
- clinicians and researchers working on fibrotic or autoimmune skin diseases
- researchers studying cytokine signalling and tissue fibrosis
- #fibrosis
- #localized scleroderma
- #il-4
- #il-13
- #cytokines
- #clinical trial
In an investigator-initiated trial, researchers have shown that inhibiting the cytokines IL-4 and IL-13 can prevent fibrosis in the skin disease localized scleroderma. These findings could pave the way for the prevention and treatment of other fibrotic conditions. The study…